DENVER, May 17 Pharmatech Oncology announces that abstracts for two studies supported by the company have been accepted for presentations during the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL, June 4-8, 2010.
The first abstract, to be presented by Dr. Chandra Belani of the Penn State Hershey Cancer Institute, included 519 patients with advanced non-small cell lung cancer. Patients received induction chemotherapy with carboplatin and gemcitabine, then were randomized to receive additional treatment with gemcitabine as maintenance therapy or best supportive care. The session will publish data on treatment safety and efficacy, including response rates and survival.
The second abstract, to be presented in a poster session by Dr. Jeffrey Vacirca of North Shore Hematology Oncology Associates, includes the first data published from an ongoing clinical trial of bendamustine and rituximab treatment for patients with relapsed or treatment refractory diffuse large B-cell lymphoma (DLBCL). This study is scheduled to enroll 54 DLBCL patients, and preliminary data will be presented on treatment safety and response rates observed thus far in the study.
Pharmatech Oncology delivers a unique approach to investigator-sponsored clinical trials (ISTs). Post-New Drug Application (NDA), publication-focused clinical trials are important milestones in the lifecycle of oncology drugs. Successful ISTs produce data to guide secondary Investigational New Drug (IND) decision-making, compendium supported off-label utilization, and advancement of patient care options in the clinic.
"Our multi-center trial ISTs are professionally and centrally administered, with diligent IND, regulatory, enrollment and data management oversight. We deliver high quality data which accurately reflect the performance of agents in community-based oncology practices," emphasizes Anders Malm, Pharmatech Oncology's CEO.
About Pharmatech Oncology, Inc.:
Pharmatech Oncology, headquartered in Denver, Colorado, is a Research Management Organization (RMO) dedicated to the highest quality of clinical research. Pharmatech Oncology provides oncology-specific Site Management Organization (SMO) and Contract Research Organization (CRO) services to its network of primarily community-based clinics. While experienced in oncology studies, the company's separate Data Management business entity is also capable of providing services for research projects in other disease indications . Pharmatech Oncology's dedication to rapid enrollment and quality data ensures successful development and utilization of therapeutic products among sponsors, investigators, and patients.
For more information about Pharmatech, please visit www.pharmatechoncology.com.
SOURCE Pharmatech Oncology